
- U 73343
- U-73122
- RHC 80267
D609PC-PLC inhibitor |
Sample solution is provided at 25 µL, 10mM.
































Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure

Related Biological Data

Description | D609 is an inhibitor of phosphatidylcholine specific phospholipase C (PC-PLC) with IC50 values of 94 µM. | |||||
Targets | PC-PLC | |||||
IC50 | 94 µM |
Cell experiment [1]: | |
Cell lines | HER2-overexpressing SKBr3 cells and various cancer cells |
Preparation method | The solubility of this compound in DMSO is > 12.7 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
Reacting condition | 50 μg/mL |
Applications | D609 inhibited PC-PLC, which enhanced HER2 internalization and lysosomal degradation, inducing down-regulation of HER2 expression on the membrane. Moreover, D609-induced PC-PLC inhibition significantly delayed HER2 re-expression on the membrane and reduced the overall cellular contents of HER2, HER2-HER3 and HER2-EGFR heterodimers. In addition, D609 also exhibited antiproliferative effects, especially in Trastuzumab-resistant cells, via PC-PLC inhibition. In breast cancer cells, D609 at the dose of 50 μg/mL decreased the activity of PC-PLC by 3.5 folds within 1hr. |
References: [1]. Paris L, Cecchetti S, Spadaro F, Abalsamo L, Lugini L, Pisanu ME, Iorio E, Natali PG, Ramoni C, Podo F. Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells. Breast Cancer Res. 2010;12(3):R27. |

D609 Dilution Calculator
calculate

D609 Molarity Calculator
calculate
Cas No. | 83373-60-8 | SDF | Download SDF |
Synonyms | D-609 potassium, D 609, D-609 | ||
Chemical Name | potassium O-(octahydro-1H-4,7-methanoinden-5-yl) carbonodithioate | ||
Canonical SMILES | S=C(S[K])OC1CC2C3C(CCC3)C1C2 | ||
Formula | C11H15KOS2 | M.Wt | 266.47 |
Solubility | ≥35.33 mg/mL in DMSO with gentle warming, ≥24.5 mg/mL in EtOH with ultrasonic and warming, ≥12.7 mg/mL in H2O | Storage | Store at -20°C |
Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
D609 is a specific and competitive inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC) with a Ki value of 6.4 μM. [1]
PC-PLC hydrolyzes (phosphatidylcholine) PC to generate 1, 2-diacylglycerol (DAG) and phosphocholine. D609 is a widely known inhibitor of PC-PLC and also inhibit sphingomyelin synthase (SMS). Due to these actions, it has antiviral and antitumor properties. D609 does not inhibit bacterial phosphatidylinositol (PI)-PLC, bovine pancreatic PLA2 or phospholipase D from cabbage[1b]. In OVCAR3 cells treated with (53 μg/mL) for 24 h, PC-PLC activity was significantly inhibited and cell proliferation was affected. In breast cancer cells, the activity of PC-PLC decreased 3.5 fold after the incubation with D609 (50 μg/ml) within 1h. The human epidermal growth factor receptor 2 (HER2) was also down-regulated [2]. D609 also has anti-inflammatory functions. It blocked the nitric oxide synthase induced by LPS (IC50=20 μg/mL) and IL-1β induced vascular cell adhesion molecule 1 gene expression in human endothelial cells.[3]
D609 can reduce sphingomyelin synthase, thereby it inhibits bFGF-stimulated astrocyte proliferation. Because of the presence of the thiol function, D609 also has antioxidant/glutathione mimetic properties[1b].
References:1.a) E. Amtmann, Drugs Exp Clin Res 1996, 22, 287-294; b) R. M. Adibhatla, J. F. Hatcher and A. Gusain, Neurochem Res 2012, 37, 671-679. 2.L. Paris, S. Cecchetti, F. Spadaro, L. Abalsamo, L. Lugini, M. E. Pisanu, E. Iorio, P. G. Natali, C. Ramoni and F. Podo, Breast Cancer Res 2010, 12, R27. 3.a) K. Tschaikowsky, M. Meisner, F. Schonhuber and E. Rugheimer, Br J Pharmacol 1994, 113, 664-668; b) R. R. Cobb, K. A. Felts, G. C. Parry and N. Mackman, Mol Pharmacol 1996, 49, 998-1004.
>ebiomall.com






>
>
>
>
>
>
>
>
>
>
>
>
而且保真性要高一点的,因为今后要用来做表达
不过。。。。我时常用那种过期一两年的。。。。也能反转出来。只要你保存得当就可以了。一般是-20以下保存。
TERT是端粒酶逆转录酶
人的端粒酶是由端粒酶逆转录酶、端粒酶RNA和一种假尿嘧啶合成酶组成
在进行RT反应之前,应考虑以下几个方面:
1、RNA
成功的cDNA合成来自高质量的RNA,高质量的RNA至少应保证全长并且不含逆转录酶的抑制剂,如EDTA或SDS。在提取RNA的过程中,要特别防止RNase的污染,同时在逆转录反应中经常加入RNase抑制剂以增加cDNA合成的长度和产量。RNase抑制剂要在第一链cDNA合成反应中,在缓冲液和还原剂(如DTT)存在的条件下加入,因为cDNA合成前的过程会使抑制剂变性,从而释放结合的可以降解RNA的RNase。蛋白RNase抑制剂仅防止RNaseA,B,C对RNA的降解,并不能防止皮肤上的RNase,因此尽管使用了这些抑制剂,也要小心不要从手指上引入RNase,实验过程中经常更换新手套。
2、引物的选择
OligodT
选择OligodT时,要求RNA必须有PolyA,所以真核生物的mRNA都适用。适合长链甚至全长mRNA的RT,所以对RNA样品的质量要求较高,最好不要有明显的DNA污染、RNA降解和RNA断裂。假如想探索新的mRNA进行RT反应,建议推荐使用OligodT引物。使用OligodT引物要比随机引物和特异性引物的稳定性要好。
随机引物
适合各种RNA的RT,尤其适合模板丰度很低的情况(比如某个gene表达量很低)。选择随机引物时,第一链cDNA合成反应中就是以所有的RNA为模板,然后进行PCR反应时设计引物进行特异性扩增。同时要注意随机引物的量和总RNA量之间的关系,一般建议每5μg总RNA的随机引物的用量为50ng,如果每5μg总RNA的随机引物的用量超过250ng,可能会导致小片段产物(<500bp)的增加和长片断、全长产物产物的降低。
特异性引物
特异性引物只能用你设计引物时的下游引物做RT,引物设计质量影响RT的结果,而且不同引物退火温度本来就不相同,所以按照说明书按照一个温度做不是最佳选择,一般不推荐。向左转|向右转

